Angioedema associated with aspirin and rofecoxib
- PMID: 15811906
- DOI: 10.1345/aph.1E546
Angioedema associated with aspirin and rofecoxib
Abstract
Objective: To report the probable association of angioedema with aspirin therapy and the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib.
Case summary: A 44-year-old white woman, previously tolerant to aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs), developed angioedema of the lips after ingesting two 325-mg aspirin tablets during one day. The reaction occurred 3 hours after taking the second aspirin and resolved within 3 hours. Two weeks later, the patient took a 25-mg rofecoxib tablet for a sore throat, and she developed angioedema 5(1/2) hours later. Although the woman took 50 mg of diphenhydramine, the swelling did not subside. She repeated the diphenhydramine dose in the evening and, by noon the next day, 26(1/2) hours after the angioedema began, it was resolved. The patient's internist prescribed an epinephrine auto-injector and advised her to consult an allergist. With skin testing and oral rechallenge with aspirin, but not rofecoxib, the allergist determined the cause of the reactions to be aspirin-induced angioedema and selective COX-2 inhibitor intolerance. The Naranjo probability scale indicated that aspirin was a highly probable cause and rofecoxib was a probable cause of this patient's angioedema.
Discussion: Aspirin-induced angioedema and NSAID intolerance have been well documented. There are reports of both tolerance and intolerance to selective COX-2 inhibitors in patients with documented allergy-like reactions to aspirin and NSAIDs.
Conclusions: Patients with aspirin and NSAID intolerance may develop intolerance to COX-2 inhibitors, especially with repeated exposure.
Similar articles
-
Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.Ann Allergy Asthma Immunol. 2005 Jan;94(1):34-8. doi: 10.1016/S1081-1206(10)61282-3. Ann Allergy Asthma Immunol. 2005. PMID: 15702813 Clinical Trial.
-
Urticaria and angioedema from cyclooxygenase-2 inhibitors.J Rheumatol. 2001 Nov;28(11):2553-4. J Rheumatol. 2001. PMID: 11708434
-
Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease.Ann Allergy Asthma Immunol. 2004 Oct;93(4):339-44. doi: 10.1016/S1081-1206(10)61392-0. Ann Allergy Asthma Immunol. 2004. PMID: 15521369 Clinical Trial.
-
[COX-2 inhibitors--one step forward and two steps back].Tidsskr Nor Laegeforen. 2005 Apr 7;125(7):875-8. Tidsskr Nor Laegeforen. 2005. PMID: 15815733 Review. Norwegian.
-
Management options for patients with aspirin and nonsteroidal antiinflammatory drug sensitivity.Ann Pharmacother. 2007 Jul;41(7):1191-200. doi: 10.1345/aph.1K023. Epub 2007 Jul 3. Ann Pharmacother. 2007. PMID: 17609236 Review.
Cited by
-
Risk of hospitalization for angio-oedema among users of newer COX-2 selective inhibitors and other nonsteroidal anti-inflammatory drugs.Br J Clin Pharmacol. 2006 Oct;62(4):496-501. doi: 10.1111/j.1365-2125.2006.02753.x. Epub 2006 Aug 30. Br J Clin Pharmacol. 2006. PMID: 16939524 Free PMC article.
-
Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature.Arch Dermatol Res. 2007 Jul;299(4):169-75. doi: 10.1007/s00403-007-0757-6. Epub 2007 May 11. Arch Dermatol Res. 2007. PMID: 17492455 Free PMC article.
-
Angioedema without urticaria after recent initiation of celecoxib.BMJ Case Rep. 2023 Sep 22;16(9):e255446. doi: 10.1136/bcr-2023-255446. BMJ Case Rep. 2023. PMID: 37739445
-
Mirabegron Associated Angioedema: A Case Report.Hosp Pharm. 2022 Dec;57(6):771-773. doi: 10.1177/00185787221095737. Epub 2022 Aug 11. Hosp Pharm. 2022. PMID: 36340626 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials